France
· Delayed Price · Currency is EUR Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of EUR 156.44 million. The enterprise value is 139.27 million.
| Market Cap | 156.44M |
| Enterprise Value | 139.27M |
Important Dates
The next estimated earnings date is Friday, April 25, 2025.
| Earnings Date | Apr 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 47.40 million shares outstanding. The number of shares has increased by 23.04% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 47.40M |
| Shares Change (YoY) | +23.04% |
| Shares Change (QoQ) | +21.39% |
| Owned by Insiders (%) | 2.70% |
| Owned by Institutions (%) | 18.71% |
| Float | 25.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.36 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.16 |
| EV / Sales | 3.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -90.97 |
Financial Position
The company has a current ratio of 1.42
| Current Ratio | 1.42 |
| Quick Ratio | 1.36 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -32.11 |
| Interest Coverage | -2.79 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.02% |
| Return on Invested Capital (ROIC) | -101.38% |
| Return on Capital Employed (ROCE) | -74.23% |
| Revenue Per Employee | 383,673 |
| Profits Per Employee | -304,300 |
| Employee Count | 102 |
| Asset Turnover | 0.66 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.00% in the last 52 weeks. The beta is 1.38, so Nanobiotix's price volatility has been higher than the market average.
| Beta (5Y) | 1.38 |
| 52-Week Price Change | -42.00% |
| 50-Day Moving Average | 3.42 |
| 200-Day Moving Average | 3.94 |
| Relative Strength Index (RSI) | 49.18 |
| Average Volume (20 Days) | 154,096 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nanobiotix had revenue of EUR 42.20 million and -33.47 million in losses. Loss per share was -0.78.
| Revenue | 42.20M |
| Gross Profit | 42.20M |
| Operating Income | -22.39M |
| Pretax Income | -33.21M |
| Net Income | -33.47M |
| EBITDA | -22.30M |
| EBIT | -22.39M |
| Loss Per Share | -0.78 |
Balance Sheet
The company has 66.34 million in cash and 49.17 million in debt, giving a net cash position of 17.17 million or 0.36 per share.
| Cash & Cash Equivalents | 66.34M |
| Total Debt | 49.17M |
| Net Cash | 17.17M |
| Net Cash Per Share | 0.36 |
| Equity (Book Value) | -21.78M |
| Book Value Per Share | -0.46 |
| Working Capital | 23.94M |
Cash Flow
In the last 12 months, operating cash flow was -1.04 million and capital expenditures -494,000, giving a free cash flow of -1.53 million.
| Operating Cash Flow | -1.04M |
| Capital Expenditures | -494,000 |
| Free Cash Flow | -1.53M |
| FCF Per Share | -0.03 |
Margins
Gross margin is 100.00%, with operating and profit margins of -53.06% and -79.31%.
| Gross Margin | 100.00% |
| Operating Margin | -53.06% |
| Pretax Margin | -78.69% |
| Profit Margin | -79.31% |
| EBITDA Margin | -52.83% |
| EBIT Margin | -53.06% |
| FCF Margin | n/a |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.04% |
| Shareholder Yield | -23.04% |
| Earnings Yield | -21.40% |
| FCF Yield | -0.98% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of -3.97. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.97 |
| Piotroski F-Score | n/a |